Evidence map›Paper›PMID 41258259›Full record

ArticleScientific reports2025

Diagnostic and prognostic values of circulating growth differentiation factor-15 and osteopontin in uterine sarcoma.

Hideaki Tsuyoshi, Tetsuya Mizutani, Masaya Uno, Tomoyasu Kato, Makoto Orisaka, Yoshio Yoshida

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hideaki TsuyoshiDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Yoshida-Gun, Fukui, 910-1193, Japan. go242h@yahoo.co.jp.
Tetsuya MizutaniDepartment of Nursing, Faculty of Nursing and Welfare Sciences, Fukui Prefectural University, Fukui, Japan.
Masaya UnoDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Tomoyasu KatoDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Makoto OrisakaDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Yoshida-Gun, Fukui, 910-1193, Japan.
Yoshio YoshidaDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-Cho, Yoshida-Gun, Fukui, 910-1193, Japan.

Funding

Japan Society for the Promotion of Science C-23K08862
6 · The paper itself

Abstract

Uterine sarcoma is an aggressive malignancy that is difficult to distinguish from benign leiomyomas pre-operatively. This study aimed to identify circulating biomarkers to improve differential diagnosis and prognostication. The serum and tissue levels of growth differentiation factor-15 (GDF15), progranulin (PGN), and osteopontin (OPN) were measured in patients with uterine sarcoma (n = 38) and leiomyoma (n = 67). The levels were correlated with diagnosis and patient survival. The serum and tissue levels of GDF15 and OPN were significantly higher in uterine sarcomas than in leiomyomas (p < 0.001). High GDF15 levels were associated with significantly poorer progression-free survival (PFS) (p < 0.001). In a multivariate analysis including established markers cancer antigen 125 (CA125) and lactate dehydrogenase (LDH), only GDF15 remained an independent predictor of PFS [hazard ratio (HR) 3.01, 95% confidence interval (CI) 1.04-8.67, p = 0.042]. The prognostic power of GDF15 was confirmed by an analysis that excluded carcinosarcomas. GDF15 and OPN are promising biomarkers for pre-operatively differentiation of uterine sarcoma from leiomyoma. Furthermore, GDF15 is a strong, independent prognostic factor for PFS in patients with uterine sarcoma and has the potential to improve diagnostic accuracy and clinical management.

Indexed as

Biomarkers, TumorGrowth Differentiation Factor 15OsteopontinSarcomaUterine NeoplasmsAdultAgedDiagnosis, DifferentialFemaleHumansLeiomyomaMiddle AgedPrognosisProgression-Free SurvivalBiomarkers, TumorGDF15 protein, humanGrowth Differentiation Factor 15OsteopontinSPP1 protein, humanCarcinosarcomaCirculating protein biomarkerGrowth differentiation factor-15OsteopontinUterine sarcoma

Identifiers

PMID41258259
PMCPMC12630631

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.